|
|
| Line 44: |
Line 44: |
| | <div class="content_conts"> | | <div class="content_conts"> |
| | <!------------------------Liver function and protection------------------------------ --> | | <!------------------------Liver function and protection------------------------------ --> |
| − | <h3 class="content_subtitle">Liver function and protection</h3> | + | <h6 class="content_sub_subtitle">Design and integration of three different modules (gshF, met K and |
| − | <p class="content_context" style="text-indent:2em; text-align:justify"> | + | cwaA)</h6> |
| − | <a href="http://www.discoverymedicine.com/category/species-and-cell-types/bacterium/lactococcus-lactis/">Lactococcus lactis</a>
| + | <p><img style="width: 70%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/4/41/T--H14Z1_Hangzhou--project_design_fig1.png"></p> |
| − | is one of the most common organisms used in bacterial drug delivery system.
| + | |
| − | <a href="http://www.discoverymedicine.com/category/species-and-cell-types/bacterium/lactococcus-lactis/">Lactococcus lactis</a>
| + | |
| − | is a food-grade bacterium that is widely used in the dairy industry. It is a
| + | |
| − | Gram-positive bacterium and therefore lacks endotoxic lipopolysaccharides (LPS) which are
| + | |
| − | associated with commonly used
| + | |
| − | <a href="http://www.discoverymedicine.com/category/species-and-cell-types/bacterium/gram-negative-bacteria/">Gram-negative bacteria</a>
| + | |
| − | . It is also non-invasive and non-commensal
| + | |
| − | and thus has less potential to trigger immunotolerance or side effects upon prolonged use. The
| + | |
| − | bacterium has an established safety profile through its long use in fermented dairy products
| + | |
| − | and is considered as a GRAS (generally recognized as safe) microorganism. During the last two
| + | |
| − | decades, significant advances have been made in the field of lactococcal genetics and protein
| + | |
| − | expression systems. The most commonly used system is the nisin-controlled gene expression
| + | |
| − | (NICE) system, containing the nisin promoter. Consequently, we have seen the emergence of new
| + | |
| − | areas for the application of engineered L. lactis for protein expression,
| + | |
| − | <a href="http://www.discoverymedicine.com/category/research-technology/nucleic-acid/gene-delivery/">gene delivery</a>,
| + | |
| − | vaccine delivery, and therapeutic
| + | |
| − | <a href="http://www.discoverymedicine.com/category/research-technology/drug-delivery-research-technology/">drug delivery.</a>
| + | |
| − | </p>
| + | |
| | | | |
| − | <p class="content_context" style="text-indent:2em; text-align:justify"> | + | <h6 class="content_sub_subtitle">Functional characterization of pNZ-SGC in L. lactis NZ9000</h6> |
| − | In the present project, since the oral table administration of GSH and SAM have some
| + | <p><img style="width: 70%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/e/e8/T--H14Z1_Hangzhou--project_design_fig2.png"></p> |
| − | disadvantages, such as low stability and short life span, here we tried to develop a novel
| + | |
| − | in-vivo strategy of produce and deliver them simultaneously by using NICE system. In the
| + | |
| − | experiment, two-functional GSH synthetase gene (gshF) and SAM synthetase gene (metK) were in
| + | |
| − | tandem inserted into the expression vector (pNZ8148), and the resulted plasmid (pNZ8148-SG) was
| + | |
| − | employed to construct the target vector pNZ8148-SGC by introducing adhesion factor gene (cwaA).
| + | |
| − | This target vector was transformed to get recombinant Lactococcus lacti, which was employed to
| + | |
| − | produce our “smart yogurt”.
| + | |
| − | </p>
| + | |
| − | <h3 class="content_subtitle">
| + | |
| − | The project is outlined with two stages：
| + | |
| − | </h3>
| + | |
| − | <!-- ------------------------Stage A---------------------------- -->
| + | |
| − | <p class="mt8 content_context">
| + | |
| − | <span style="width:120px; font: bold; font-size: 25px">Stage A</span><span>Construction of Lactococcus lactis NZ9000/pNZ-SGC</span>
| + | |
| − | </p>
| + | |
| − | <p><img style="width: 50%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/b/be/T--H14Z1_Hangzhou--description_projectOverview_fig1.png"></p>
| + | |
| − | <p><img style="width: 50%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/c/cd/T--H14Z1_Hangzhou--description_projectOverview_fig12.png"></p>
| + | |
| − | <p><img style="width: 50%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/8/87/T--H14Z1_Hangzhou--description_projectOverview_fig3.png"></p> | + | |
| | | | |
| − | <!-- ------------------------Stage B---------------------------- --> | + | <h6 class="content_sub_subtitle">Production of “smart yogurt” with our constructed L. lactis |
| − | <p class="mt8 content_context"> | + | NZ9000/pNZ-GMcA</h6> |
| − | <span style="width:120px; font: bold; font-size: 25px">Stage B</span><span>Preparation of smart yogurt with our constructed Lactococcus lactis</span>
| + | <p><img style="width: 70%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/6/65/T--H14Z1_Hangzhou--project_design_fig3.png"></p> |
| | + | <p class="content_context" style="text-align:center; font-size:8px"> |
| | + | (adapted from <a href="https://www.nyas.org/ebriefings/cytokine-therapies/">https://www.nyas.org/ebriefings/cytokine-therapies/</a>) |
| | </p> | | </p> |
| − | <p><img style="width: 50%; margin-top: 1em" src="https://static.igem.org/mediawiki/2018/6/66/T--H14Z1_Hangzhou--description_projectOverview_fig4.png"></p>
| |
| | </div> | | </div> |
| | </div> | | </div> |
